Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Ningetinib in Advanced NSCLC With MET Exon 14 Skipping Mutations

NCT04992858 is registered in ClinicalTrials.gov with Sunshine Lake Pharma Co., Ltd. as lead sponsor.

NCT NCT04992858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04992858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Ningetinib in Advanced NSCLC With MET Exon 14 Skipping Mutations
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Phase
Phase 2
Overall status
Withdrawn
Start date
November 27, 2022
Completion date
December 9, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nsclc